AK119 + AK112 + mFOLFOX6

This is an experimental **combination therapy** consisting of three components: - **AK119**: an investigational monoclonal antibody targeting CD73 (ecto-5’-nucleotidase), being developed as an immuno-oncology agent to inhibit adenosine-mediated immune suppression in the tumor microenvironment, with the intention to enhance anti-tumor immune response. - **AK112**: an investigational bispecific monoclonal antibody targeting PD-1 and VEGF, designed to provide checkpoint inhibition (PD-1) and anti-angiogenic (VEGF) effects concurrently, aiming to maximize immune-mediated anti-tumor activity and inhibit tumor-driven vascularization. - **mFOLFOX6**: a standard-of-care cytotoxic chemotherapy regimen comprised of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU), widely used for gastrointestinal cancers, particularly colorectal cancer[1][2][5]. mFOLFOX6 works primarily by disrupting DNA synthesis and repair, and is administered intravenously. The combined therapy is being investigated (2023–2025) primarily for **advanced or metastatic colorectal cancer** and other gastrointestinal malignancies as part of clinical trials. The rationale is to simultaneously target multiple pathways of tumor growth: immune suppression (AK119), immune checkpoint and angiogenesis (AK112), and direct cytotoxicity (mFOLFOX6).